Table 2. Correlation between LSM values and other variables.
| Independent variables | Univariatea | Multivariate |
| r (P-value) | β (P-value) | |
| Age, years | 0.002 (0.984) | – |
| Time since HIV infection diagnosis, months | −0.086 (0.412) | – |
| Total duration of cART, months | −0.011 (0.917) | – |
| CD4+ T lymphocyte counts, cells/mm3 | ||
| At LSM examination | −0.186 (0.074) | −0.755 (0.452) |
| Nadir | −0.039 (0.714) | – |
| Plasma HIV-RNA viral load, copies/mL | ||
| At LSM examination | −0.017 (0.868) | – |
| Log10(highest value after the HIV diagnosis) | 0.090 (0.402) | – |
| Body mass index, kg/m2 | −0.025 (0.819) | – |
| Alanine aminotransferase (IU/L) | 0.120 (0.251) | – |
| Alkaline phosphatase (IU/L) | 0.143 (0.170) | – |
| Total bilirubin (mg/dL) | −0.037 (0.725) | – |
| γ-glutamyltranspeptidase (IU/L) | 0.119 (0.525) | – |
| Prothrombin time, INR | 0.181 (0.241) | – |
| Platelet count, X 103/mm3 | −0.112 (0.287) | – |
| Cumulative exposure duration of antiretroviral drugs, monthsb | ||
| NRTIs | ||
| Zidovudine (n = 68) | 0.127 (0.301) | ― |
| Stavudine (n = 25) | −0.247 (0.234)c | ― |
| Didanosine (n = 39) | 0.117 (0.477) | ― |
| Abacavir (n = 23) | −0.059 (0.788)c | ― |
| NNRTIs (n = 54) | 0.230 (0.095) | ― |
| PIs (n = 58) | 0.043 (0.747) | |
| Boosted (n = 50) | −0.241(0.092) | −0.234 (0.023) |
| Unboosted (n = 31) | 0.401 (0.025) | 0.430 (<0.001) |
NOTE. aPearson’s correlation coefficient, bCorrelation analyses in only patients who has ever been received each antiretroviral drug, cSpearman’s ρ. LSM, liver stiffness measurement; cART, combined antiretroviral treatment; INR, international normalized ratio; NRTIs, nucleoside analogue reverse transcriptase inhibitors; NNRTIs, non-nucleoside analogue reverse transcriptase inhibitors; PIs, protease inhibitors.